<DOC>
	<DOCNO>NCT01041040</DOCNO>
	<brief_summary>Prospective , multicenter , uncontrolled cohort study analyze efficacy risk adapt treatment strategy , include gemtuzumab ozogamicin ( GO ) consolidation , patient acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>LAM07 : Study Analyze Efficacy Risk Adapted Treatment Strategy , Including Gemtuzumab Ozogamicin ( GO ) During Consolidation , Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Patients stratify accord age first step , cut-point 65 year old . For patient young 65 year old achieve complete response , second stratification make first consolidation treatment . This second stratification perform accord follow parameter : MDR end induction , karyotype molecular finding , include FLT3 internal tandem duplication ( ITD ) NPM1 mutation . The follow group identify accord parameter : Group A : Patients age 65 young candidate intensive chemotherapy . Group A1 : Patients first CR negative MRD ( less 0.1 % ) , good prognosis karyotype , case ( 8 ; 21 ) inv ( 16 ) , absence mutation exon 17 c-kit . Group A2 : Patients first CR negative MRD ( less 0.1 % ) , intermediate-risk karyotype , NPM1 positive FLT3 negative . Group A3 : Patients first CR negative MRD ( less 0.1 % ) , intermediate-risk karyotype , absence NPM1 mutation negative FLT3-ITD FLT3-ITD positive ratio less 0.8 , regardless NPM1 status . Group A4 : Patients first CR positive MRD ( great 0.1 % ) , ( 8 ; 21 ) inv ( 16 ) mutation exon 17 c-kit , intermediate risk karyotype positive FLT3-ITD ratio great equal 0.8 high-risk karyotype . Group B : Patients 65 year able receive intensive chemotherapy . TREATMENT SCHEDULE : Treatment tailor previously define group : Group A : Induction Idarubicin ARA-C `` 3 +7 '' schedule ( IDA 12 mg/m2 x 3 day ARA-C 200 mg/m2 x 7 day ) . Group A1 : Two consolidation cycle ARA-C dose 3 g/m2 day 1 , 3 5 . Collection peripheral blood stem cell ( PBSC ) first consolidation . Autologous stem cell transplantation ( ASCT ) Busulphan 1 mg/kg/6 VO 0,8 mg/kg/6 h IV ( Busilvex® ) day -8 -5 ; Etoposide 20 mg/kg/d day -4 -3 ARA-C 3 g/m2/12 h day -3 -2 ( see criterion HiDAC modification ) ; G-CSF 10 µg/kg/d day -9 -2 ( BEA schedule ) . Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) recommend first CR group patient . Group A2 : First consolidation Idarubicin ARA-C dose induction plus GO 3 mg/m2 day 1 . Collection PBSC first consolidation . Second consolidation ARA-C 3 g/m2 day 1 , 3 5 follow ASCT BEA conditioning . It recommend perform Allo-HSCT , especially alternative donor , first CR . Group A3 : First consolidation Ida ARA-C dose induction plus GO 3 mg/m2 day 1 . Collection PBSC first consolidation . Second consolidation ARA-C 3 g/m2 day 1 , 3 5 follow ASCT BEA schedule HLA-identical sibling available . Patients group candidate allo-HSCT first CR HLA-identical sibling available . Allo-HSCT perform first consolidation . Group A4 : First consolidation Ida ARA-C dose induction plus GO 3 mg/m2 day 1 . Collection PBSC first consolidation . Second consolidation ARA-C 3 g/m2 day 1 , 3 5 follow ASCT BEA schedule donor available . Patients group candidate allo-HSCT first CR , include alternative donor . Allo-HSCT perform first consolidation later donor available time . Group C : Induction Idarubicin ARA-C `` 2 + 5 '' ( IDA 12 mg/m2 x 2 day ARA-C 200 mg/m2 x 5 day ) . Two consolidation GO 3 mg/m2 day 1 ARA-C 100 mg/m2 continuous infusion day 1 5 . AML CHARACTERIZATION AND SAMPLES COLLECTION : To achieve complete characterization AML , inmunophenotype analysis ( define pattern MRD study ) , cytogenetics , FISH inv ( 16 ) , ( 8 ; 21 ) ( 15 ; 17 ) , molecular study AML1/ETO , CBFβ/MYH11 , NPM1 FLT3-ITD perform case . For FLT3-ITD , ratio mutate mutate allele calculate . During phase sample collection , DNA , RNA viable cell store .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>For intensive chemotherapy : 1 . Patients novo AML secondary MDS previous treatment , regardless age . 2 . Signed write informed consent . 3 . ECOG ≤ 2 . If ECOG great 2 due AML , patient include study . 4 . LVEF &gt; 40 % measure mean echocardiography . 5 . If background respiratory disease ( related AML ) , risk factor clinical criterion COPD , value functional test , include DLCO , great 50 % expect . 6 . Bilirubin , alkaline phosphatase ALT &lt; 3 fold upper normal value , provide due disease motivates treatment ( AML ) . 7 . Serum creatinine &lt; 2,5 mg/dL provide due disease motivates treatment ( AML ) . 8 . In fertile aged woman , negative pregnancy test use contraception method require . Any patient meet inclusion exclusion criterion treatment intensive chemotherapy evaluate individually consider could still obtain benefit treatment consider could still obtain benefit treatment . Criteria GO administration patient candidate intensive chemotherapy Same criterion intensive chemotherapy , include follow specification : 1 . CD33 positive ( 5 % leukemic population ) 2 . Exclusion treatment GO case serious hepatic disease due AML . 3 . In patient go receive GO two cycle , second one administrate toxicity due first cycle recover . 4 . Though GO administer dose much low usual , recommended period two month GO administration hematopoietic stem cell transplantation ( HSCT ) . Criteria modification high dose ARAC The dose AraC cycle contain HiDAC reduce follow case : 1 . The hematopoietic recovery previous cycle longer 28 day . 2 . Presence previous cycle confluent maculopapular rash druginduced shed . 3 . More 4 episode watery diarrhea per day . 4 . Increase 4 fold previous normal value aminotransferases alkaline phosphatase cycle . 5 . Total bilirubin great 3 mg/dL cycle . 6 . Treatment HiDAC definitively suspend ( even include BEA condition ) previous toxicity include severe cerebellar ataxia , confusion another sign central nervous toxicity another clear explanation . 1 . Patients blastic crisis chronic myeloid leukemia myeloproliferative syndrome evolve acute leukemia . 2 . Patients AML relapse . 3 . Acute promyelocytic leukemia ( M3 M3v ) . 4 . Absence sign write informed consent . 5 . ECOG ≥ 3 due disease motivates treatment ( AML ) . 6 . LVEF &lt; 40 % determine echocardiography study . 7 . Values respiratory functional test , include DLCO , low 50 % expect . 8 . Bilirubin , alkaline phosphatase GOT &gt; 3 fold upper normal value , provide due disease motivates treatment ( AML ) . 9 . Serum creatinine &gt; 2.5 mg/dL provide due disease motivates treatment ( AML ) . 10 . Positive pregnancy test use effective contraception fertile age woman . 11 . Previous treatment antileukemic chemotherapy , except hydroxyurea . 12 . Presence active neoplasia different AML . 13 . Presence serious psychiatric disease . 14 . Positive HIV test . 15 . Any condition limit dissuade treatment intensive chemotherapy , especially anthracyclines</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Acute Myeloblastic Leukemia</keyword>
</DOC>